CEFEPIME IN PLASTIC CONTAINER (cefepime hydrochloride) · Baxter
Cefepime is a fourth-generation cephalosporin antibiotic indicated for the treatment of moderate to severe pneumonia, uncomplicated and complicated urinary tract infections (including pyelonephritis), and uncomplicated skin and skin structure infections. It is also used as empiric monotherapy for febrile neutropenic patients and in combination with metronidazole for the treatment of complicated intra-abdominal infections. To maintain effectiveness and reduce the development of drug-resistant bacteria, cefepime should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.
How CEFEPIME IN PLASTIC CONTAINER Works
Cefepime is a bactericidal antibacterial agent that acts by inhibiting bacterial cell wall synthesis. It exerts its effect by binding to specific penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, which prevents the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Details
- Status
- Prescription
- First Approved
- 2008-08-05
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CEFEPIME IN PLASTIC CONTAINER Approval History
What CEFEPIME IN PLASTIC CONTAINER Treats
5 indicationsCEFEPIME IN PLASTIC CONTAINER is approved for 5 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.
CEFEPIME IN PLASTIC CONTAINER Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CEFEPIME IN PLASTIC CONTAINER
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT01484015 | IRB00015247 NCI-2011-02422, CCCWFU 02110 | Ph 1 | completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFEPIME IN PLASTIC CONTAINER FDA Label Details
Indications & Usage
FDA Label (PDF)Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia Empiric therapy for febrile neutropenic patients Uncomplicated and complicated urinary tract infections Uncomplicated skin and skin structure infections Complicated intra-abdominal infections (used in combination with metronidazole) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial dr...
Track CEFEPIME IN PLASTIC CONTAINER with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.